The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study compares the efficacy and tolerability of 12 weeks of open-label duloxetine in adult outpatients with anxious versus non-anxious depression. METHODS: Participants in a major depressive episode (N=249) began duloxetine treatment at 30 or 60 mg daily for the first week, followed by up to 11 weeks of flexibly dosed duloxetine (60, 90, or 120 mg daily). Efficacy measures included HAMD17, HAMA, and CGI-S. Safety and tolerability were assessed by early discontinuation and adverse event rates. Anxious depression was defined by a HAMD17 Anxiety/Somatization Factor score>or=7. RESULTS: Duloxetine treatment was associated with a significantly greater reduction in total HAMD17 scores and HAMD17 Anxiety/Somatization Factor scores among patients with anxious depression compared to non-anxious depression. Differences in CGI-S and HAMA scores at the end of the trial between groups were not statistically significant. Remission and response rates at endpoint were similar between groups, but anxious depressives had a significantly shorter median time to response. Discontinuation rates due to any reason, discontinuation due to adverse events, and treatment-emergent adverse events were similar between groups, except for the significantly greater occurrence of influenza in anxious depressives. CONCLUSIONS: Duloxetine's efficacy in anxious depression was somewhat superior to non-anxious depression; tolerability was comparable between groups.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“And these cases indeed occur in trials [20] as well as in practice [22].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [20]
In the citing paper
“Re-analyzing the Beta-Blocker Heart Attack Trial, Horwitz et al. [20] found that propranolol reduced the risk of dying for the 'average' patient who survived an acute myocardial infarction, whereas it was harmful in a subgroup of patients characterized by specific co-therapy histories.”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [20]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Participants were required to have a 17-item Hamilton Rating Scale for Depression (HAMD17) (20) total score ≥15, and a Clinical Global Impression-Severity of Illness (CGI-S) (21) score ≥4 at two consecutive screening visits.”
MethodThe assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 9×
“Efficacy measures included the HAMD17 total score, the Hamilton Rating Scale for Anxiety (HAMA) (23) total score, the CGI-S scale, and the HAMD17 Anxiety/Somatization subscale (6,24).”
MethodInfluential(1976) · Medical Entomology and Zoology · Cited by 8,899
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959 · cited 1×
“Response was defined as a ≥ 50% reduction in HAMD17 total score from baseline, whereas remission was defined as a HAMD17 total score ≤ 7 (25).”
MethodDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“Prior exposure to antidepressant treatment was assessed with the selfrated Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) (22) administered by automated Interactive Voice Response (IVR) via a touch tone telephone.”
MethodBymaster, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00298-6 · Cited by 717
FAVA, M., ALPERT, J. E., CARMIN, C. N., WISNIEWSKI, S. R., TRIVEDI, M. H., BIGGS, M. M., SHORES-WILSON, K., MORGAN, D., SCHWARTZ, T., BALASUBRAMANI, G. K., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291704002612 · Cited by 406 · cited 5×
“Efficacy measures included the HAMD17 total score, the Hamilton Rating Scale for Anxiety (HAMA) (23) total score, the CGI-S scale, and the HAMD17 Anxiety/Somatization subscale (6,24).”
BackgroundMethodDuloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Van Valkenburg, C., Akiskal, H. S., Puzantian, V., & Rosenthal, T. (1984) · Journal of Affective Disorders · doi:10.1016/0165-0327(84)90009-0 · Cited by 282 · cited 1×
“Anxious depression has often been defined in the literature as MDD with high levels of anxiety symptoms and has been found to be associated with greater severity of illness as well as with greater functional impairment (2), chronicity (3), delayed response to treatment (4), and an increased risk of suicidality (5).”
Background
Cited by
Current perspectives of the roles of the central norepinephrine system in anxiety and depression
Goddard, A. W., Ball, S. G., Martinez, J., Robinson, M. J., Yang, C. R., Russell, J. M., & Shekhar, A. (2010) · Depression and Anxiety · doi:10.1002/da.20642 · Cited by 316
“Our current views on the importance of the central NE system in anxious depression come from clinical studies showing efficacy of selective norepinephrine reuptake inhibitors (NRI) and the dual serotonin/NE reuptake inhibitors,([61,65,66]) although there is a lack of differential efficacy in these classes of antidepre…”
BackgroundSelf-citationComorbid Anxiety and Depression: Clinical and Conceptual Consideration and Transdiagnostic Treatment
Choi, K. W., Kim, Y.-K., & Jeon, H. J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_14 · Cited by 304
Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158
“The MGH ATRQ has been used in several multi-center studies in TRD, including those involving the study of duloxetine [7,8], mirtazapine [9], and aripiprazole [10,11] in TRD.”
MethodBlood, A. J., Iosifescu, D. V., Makris, N., Perlis, R. H., Kennedy, D. N., Dougherty, D. D., Kim, B. W., Lee, M. J., Wu, S., Lee, S., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013945 · Cited by 126
Liu, C.-H., Ma, X., Song, L.-P., Fan, J., Wang, W.-D., Lv, X.-Y., Zhang, Y., Li, F., Wang, L., & Wang, C.-Y. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.047 · Cited by 71
“llness, longer illness chronicity, and a higher risk of disability nd suicidal tendency [4–6].”
Metadata
- Authors
- Fava, M., Martinez, J. M., Greist, J., Marangell, L. B., Brown, E., Chen, L., & Wohlreich, M. M.
- Affiliations
- Eli Lilly (United States) (US)
- Healthcare Technology Systems (US)
- Baylor College of Medicine (US)
- Venue
- Annals of Clinical Psychiatry
- Publisher
- SAGE Publications
- Published
- 2007-07
- Volume
- 19
- Issue
- 3
- Pages
- 187-195
- ISSN
- 1040-1237 (ISSN-L)
- 1547-3325
- OpenAlex
- W2059939716
- Cited by
- 25
- References
- 22
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 1 · 2020: 2 · 2018: 2 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 2
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Annals of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- duloxetine, anxious depression, major depressive episode, antidepressant efficacy, tolerability, treatment-emergent adverse events, influenza, time to response
- MeSH terms
- Duloxetine Hydrochloride, Adult, Antidepressive Agents, Anxiety, Depressive Disorder, Female, Humans, Male, Outpatients, Safety, Thiophenes, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study. https://app.cochat.ai/papers/10.1080/10401230701465178
- The paper
- Fava, M., Martinez, J. M., Greist, J., Marangell, L. B., Brown, E., Chen, L., & Wohlreich, M. M. (2007). The Efficacy and Tolerability of Duloxetine in the Treatment of Anxious Versus Non-Anxious Depression: A Post-Hoc Analysis of an Open-Label Outpatient Study. Annals of Clinical Psychiatry. https://doi.org/10.1080/10401230701465178
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.